Innate Therapeutics Ltd co-locates its CSO in the IIB

Innate Therapeutics Ltd has taken an office in the IIB and co-located its Chief Scientific Officer, Dr Gill Webster. The company has designed and manufactured a unique immunomodulator microparticle technology which can be used to induce the immune system to fight certain cancers and infections, or turn off certain immune mechanisms involved in autoimmune diseases. By attaching selected modulators to the microparticle, these triggers can be delivered reliably to specific cells of the immune system.